Page 2 - Huma Qamar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Huma Qamar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Huma Qamar Today - Breaking & Trending Today

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Published: April 8, 2024

MALVERN, Pa., April 08, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the...

Source: marketscreener.com

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Published: April 5, 2024

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 -- Ocugen, Inc. , a...

Source: marketscreener.com

Why Ocugen Stock Is Climbing Today - Ocugen (NASDAQ:OCGN)

Published: April 5, 2024

Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

Source: benzinga.com